Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
Stopped early · Phase 1
Conditions studied: Solid Malignancies
In brief
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
Key facts
- Study ID
- NCT05006794
- Run by
- Gilead Sciences
- People needed
- 37
- Starts
- 2021-09-15
- Expected to finish
- 2025-06-16
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora, Colorado, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- START Midwest — Grand Rapids, Michigan, United States
- Montefiore Medial Center - Montefiore Medical Park — The Bronx, New York, United States
- Novant Health Cancer Institute - Elizabeth (Breast Cancer) — Charlotte, North Carolina, United States
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States
- Oregon Health Oregon Health & Sciences University-Knight Cancer Institute — Portland, Oregon, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- START San Antonio — San Antonio, Texas, United States
- START Mountain Region — West Valley City, Utah, United States
- Rambam Health Care Campus — Haifa, Israel
- Hadassah Medical Center- Ein Kerem — Jerusalem, Israel
- Tel-Aviv Sourasky Medical Center — Tel Aviv, Israel
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.